Biomarkers Correlated with Idiopathic Inflammatory Myopathy
By LabMedica International staff writers Posted on 25 Sep 2018 |
Image: The Immage 800 immunochemistry system (Photo courtesy of Beckman Coulter).
Patients with idiopathic inflammatory myositis (IIM) typically present with muscle weakness, myalgia and in case of dermatomyositis (DM) also skin involvement. Arthralgia is often present, but the articular manifestations are usually mild and non-destructive.
As rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs) are not routinely tested in idiopathic inflammatory myositis (IIM), little is known about their prevalence and clinical implications in this patient group. In anti-synthetase syndrome (ASS), presence of ACPA is reportedly associated with more severe and erosive arthritis.
Medical scientists at the University Hospitals Leuven (Leuven, Belgium) analyzed serum samples from 121 patients. Thirty diagnosed with polymyositis, 41 with dermatomyositis, 37 with ASS, five with necrotizing autoimmune myopathy or seven with overlap myositis and one with inclusion body myositis. RF was evaluated by nephelometry; anti-CCP antibodies were identified using fluoro enzyme immunoassays. Values above 40 IU/mL and 7 U/mL were considered positive for RF and ACPA, respectively.
The investigators observed no significant differences were observed between RF-positive and RF- negative IIM patients. The prevalence of RF and ACPA was 9.09% and 4.96%, respectively. The team observed a trend for RF-positive IIM patients to be older than RF-negative IIM patients and to more frequently carry ACPA antibodies and have lower forced expiratory volume in 1 second (FEV1) values (72% versus 88%). There was no statistically significant difference between patients who tested positive for both RF and ACPA, and patients who tested negative for both antibodies. The presence of RF or ACPA was not significantly associated with interstitial lung disease.
The authors concluded that their study demonstrated that RF and ACPA are prevalent in patients with IIM, but the detected prevalence is lower than the prevalence reported in previous studies in connective tissue diseases including IIM. Their results did not show a clear association between RF or ACPA positivity and specific clinical features or the occurrence of ILD or arthritis. The study was published originally published online on July 25, 2018, in the journal RMD Open.
Related Links:
University Hospitals Leuven
As rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs) are not routinely tested in idiopathic inflammatory myositis (IIM), little is known about their prevalence and clinical implications in this patient group. In anti-synthetase syndrome (ASS), presence of ACPA is reportedly associated with more severe and erosive arthritis.
Medical scientists at the University Hospitals Leuven (Leuven, Belgium) analyzed serum samples from 121 patients. Thirty diagnosed with polymyositis, 41 with dermatomyositis, 37 with ASS, five with necrotizing autoimmune myopathy or seven with overlap myositis and one with inclusion body myositis. RF was evaluated by nephelometry; anti-CCP antibodies were identified using fluoro enzyme immunoassays. Values above 40 IU/mL and 7 U/mL were considered positive for RF and ACPA, respectively.
The investigators observed no significant differences were observed between RF-positive and RF- negative IIM patients. The prevalence of RF and ACPA was 9.09% and 4.96%, respectively. The team observed a trend for RF-positive IIM patients to be older than RF-negative IIM patients and to more frequently carry ACPA antibodies and have lower forced expiratory volume in 1 second (FEV1) values (72% versus 88%). There was no statistically significant difference between patients who tested positive for both RF and ACPA, and patients who tested negative for both antibodies. The presence of RF or ACPA was not significantly associated with interstitial lung disease.
The authors concluded that their study demonstrated that RF and ACPA are prevalent in patients with IIM, but the detected prevalence is lower than the prevalence reported in previous studies in connective tissue diseases including IIM. Their results did not show a clear association between RF or ACPA positivity and specific clinical features or the occurrence of ILD or arthritis. The study was published originally published online on July 25, 2018, in the journal RMD Open.
Related Links:
University Hospitals Leuven
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form